Biotech and certain aspects of the health care and life sciences sector can often see incredible surges from day to day. The group can also witness many implosions on bad news as well. 24/7 Wall St. is tracking four huge gainers running up in the double digits on Tuesday. These are all very actively traded so far on the day and seeing this many big movers is not normal even for a sector full of volatility. We have also seen a huge loser on bad drug study news.

Cytori Therapeutics Inc. (NASDAQ: CYTX), Endo Health Solutions Inc. (NASDAQ: ENDP), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), and Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) are the big gainers. ImmunoGen, Inc. (NASDAQ: IMGN) is the serious loser on Tuesday.

We are tracking mid-day trading gains prior to 1:00 p.m. EST. As a reminder, none of these stocks would pass suitability tests for widows and orphans. They are all highly speculative stocks.

Cytori Therapeutics Inc. (NASDAQ: CYTX) is up a sharp 68% to $3.49 on more than 9.5 million shares. This is after Cytori Therapeutics licensed Asia-Pacific cardiovascular, renal & diabetes markets to Lorem Vascular. If accurate, this could represent up to $531 million for the company if all performance hurdles are hit. Its market cap is only about $240 million, even after this big surge. Keep in mind that this is said to be a 30-year licensing pact.

Endo Health Solutions Inc. (NASDAQ: ENDP) is up 29% at $56.27 on over 24 million shares. This is about 15-times normal trading volume. The company beat earnings and is making a $1.5 billion acquisition of Paladin Labs. Shares hit a new high of $58.23 earlier in the day. It turns out that Endo is looking to grow into a larger company even by acquiring that growth.

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is trading up by 22% to $13.60 on more than 10 million shares. The company announced that its Zerenex, a ferric citrate coordination complex, met all primary and key secondary endpoints in its Phase II study of non-dialysis dependent chronic kidney disease patients with elevated serum phosphorus and iron. This is now about 5-times normal trading volume and the stock hit a yearly high of $14.07 earlier in the day. This move took the market cap up to over $1.1 billion, and that makes this story something to watch as many investors will not touch a biotech or emerging healthcare stock until the $1 billion market capitalization has been hit.

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) is enjoying a second day of gains after a stellar Monday. This stock is up over 50% at $8.05 on over 20 million shares. This stock is a micro-cap stock that traded under 100,000 shares on many recent days. The stock almost doubled one day last week up to $2.81 and it has risen steadily each day since. This stock has been around forever and things were bad enough that it had to do a serious reverse stock split earlier in the year.

ImmunoGen, Inc. (NASDAQ: IMGN) is a serious unhealthy loser. The company halted its lung cancer trial which was supposed to be a smart-bomb treatment that targets tumors and leaves other tissue undamaged. Shares had seen some caution ahead of this, so some of the bad news might have been known. Still, the stock is down 20% at $13.16 on about 3.8 million shares in mid-day trading. That is already over 5-times normal volume and the stock’s 52-week range is $10.85 to $20.25.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.